

October 7, 2022

Company Name: HEALIOS K.K.  
Representative: Hardy TS Kagimoto, Chairman & CEO  
(TSE Growth Code: 4593)

**TREASURE study results to be presented  
at the 40th Annual Meeting of Japan Society of Neurological Therapeutics**

HEALIOS K.K. (“Healios”) announces that the results of the “TREASURE” study, its clinical trial conducted in Japan for ischemic stroke patients, will be presented in a ‘Symposium 2’ session at the 40<sup>th</sup> Annual Meeting of Japan Society of Neurological Therapeutics to be held in Japan from November 2 to 4, 2022.

Date: November 2, 2022, 9:40-11:40am Slot (local time)

Title: The Advancement of Stroke Therapy and the Dawn of Cellular Therapy

Presenter: Toshiya Osanai, Ph.D, Hokkaido University, Department of Neurosurgery

Venue: Hotel Hamatsu (3-18 Toramarumachi, Koriyama City, Fukushima Prefecture),

Venue 2 for the Annual meeting

Annual meeting URL: <http://www.congre.co.jp/jsnt2022/index.html>

About the TREASURE study

The TREASURE study was conducted to investigate the safety and efficacy of HLCM051 (Multistem®) in patients with ischemic stroke. The study targeted patients with moderate to moderate-severe strokes (baseline NIHSS score 8-20), with administration of a single dose of HLCM051 intravenously within 18-36 hours from stroke onset. The trial was conducted at 48 sites in Japan and enrolled 206 patients. HLCM051 is an off-the-shelf, somatic stem cell regenerative medicine product that Healios is developing for both ischemic stroke and acute respiratory distress syndrome in Japan.

Contact:  
IR & Finance and Accounting Division, HEALIOS K.K.  
E-mail: [ir@healios.jp](mailto:ir@healios.jp)